Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG low-dose rituximab maintenance in ITP
MOH_2019-08-27_007366Phase 3Recruiting
- Sponsor
- Ospold Hospital
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab and dexamethasone in immune thrombocytopenia (ITP) (4 arms), sponsored by Ospold Hospital. Started Apr 2019; status: recruiting.
02
Drugs
rituximabdexamethasone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2019-08-27_007366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-27_007366.